HRP20040832A2 - Microorganism for genetic therapeutic treatment of proliferative diseases - Google Patents

Microorganism for genetic therapeutic treatment of proliferative diseases

Info

Publication number
HRP20040832A2
HRP20040832A2 HRP20040832A HRP20040832A2 HR P20040832 A2 HRP20040832 A2 HR P20040832A2 HR P20040832 A HRP20040832 A HR P20040832A HR P20040832 A2 HRP20040832 A2 HR P20040832A2
Authority
HR
Croatia
Prior art keywords
microorganism
tumor
component
protein
cells
Prior art date
Application number
Other languages
English (en)
Croatian (hr)
Inventor
Ulf R Rapp
Werner Goebel
Hans-Harald Sedlacek
Joachim Fensterle
Ivaylo Gentschev
Original Assignee
Ulf R Rapp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ulf R Rapp filed Critical Ulf R Rapp
Publication of HRP20040832A2 publication Critical patent/HRP20040832A2/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01031Beta-glucuronidase (3.2.1.31)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76Albumins
    • C07K14/765Serum albumin, e.g. HSA
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405Glucanases
    • C12N9/2434Glucanases acting on beta-1,4-glucosidic bonds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/16Exonucleases active with either ribo- or deoxyribonucleic acids and producing 3'-phosphomonoesters (3.16)
    • C12Y301/16001Spleen exonuclease (3.1.16.1), i.e. 5->3 exoribonuclease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
HRP20040832 2002-02-14 2004-09-14 Microorganism for genetic therapeutic treatment of proliferative diseases HRP20040832A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10206325A DE10206325A1 (de) 2002-02-14 2002-02-14 Ummantelter Mikroorganismus
PCT/DE2003/000470 WO2003068954A2 (de) 2002-02-14 2003-02-13 Mikroorganismus zur gentherapeutischen behandlung proliferativer erkrankungen

Publications (1)

Publication Number Publication Date
HRP20040832A2 true HRP20040832A2 (en) 2004-12-31

Family

ID=27674670

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20040832 HRP20040832A2 (en) 2002-02-14 2004-09-14 Microorganism for genetic therapeutic treatment of proliferative diseases

Country Status (19)

Country Link
US (1) US20050244374A1 (es)
EP (1) EP1474519A2 (es)
JP (1) JP2005517405A (es)
KR (1) KR20040103941A (es)
CN (1) CN1646693A (es)
AU (1) AU2003206663B2 (es)
BR (1) BRPI0307722A2 (es)
CA (1) CA2513198A1 (es)
DE (2) DE10206325A1 (es)
HR (1) HRP20040832A2 (es)
IL (1) IL163553A0 (es)
MX (1) MXPA04007934A (es)
NO (1) NO20043800L (es)
NZ (1) NZ535310A (es)
PL (1) PL372901A1 (es)
RS (1) RS72404A (es)
RU (1) RU2004127459A (es)
WO (1) WO2003068954A2 (es)
ZA (1) ZA200407358B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005260697B2 (en) * 2004-06-29 2011-10-06 Anticancer, Inc. Cancer selective auxotrophs
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAx抗-CD3抗體及其用途
US11519007B2 (en) 2019-02-22 2022-12-06 Arizona Board Of Regents On Behalf Of Arizona State University Tumor-navigating, self-eradicating, trail-armed salmonella for precision cancer therapy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19720761A1 (de) * 1997-05-07 1998-11-12 Schering Ag Verfahren zur Synthese und Sekretion von zur Kontrazeption geeigneter Proteine oder Proteinfragmente durch attenuierte Salmonellen oder einen anderen Gram-negativen attenuierten Impfstamm zur Erzeugung einer oralen Vakzinierung

Also Published As

Publication number Publication date
PL372901A1 (en) 2005-08-08
NO20043800L (no) 2004-11-08
US20050244374A1 (en) 2005-11-03
WO2003068954A2 (de) 2003-08-21
AU2003206663B2 (en) 2007-11-01
WO2003068954A8 (de) 2005-10-13
JP2005517405A (ja) 2005-06-16
WO2003068954A3 (de) 2003-10-16
MXPA04007934A (es) 2005-11-23
KR20040103941A (ko) 2004-12-09
BRPI0307722A2 (pt) 2017-07-04
ZA200407358B (en) 2005-11-18
CN1646693A (zh) 2005-07-27
CA2513198A1 (en) 2003-08-21
EP1474519A2 (de) 2004-11-10
AU2003206663B9 (en) 2003-09-04
AU2003206663A1 (en) 2003-09-04
RS72404A (en) 2006-12-15
DE10390506D2 (de) 2005-01-13
RU2004127459A (ru) 2005-05-10
IL163553A0 (en) 2005-12-18
NZ535310A (en) 2008-04-30
DE10206325A1 (de) 2003-09-04

Similar Documents

Publication Publication Date Title
US11104916B2 (en) Compositions and methods for alphavirus vaccination
JP2005531507A (ja) ストローマ細胞前駆体による抗癌物質の局所的な産生および/または送達方法
US20080187520A1 (en) Tool for the transfer and production of proteins using the pseudomonas type III secretion system
JP2004500042A (ja) エフェクター分子の腫瘍標的送達のための組成物および方法
JPH08510911A (ja) 遺伝子治療に適するプラスミド
JP2000503004A (ja) 化合物を細胞に輸送するための毒素ペプチドおよび/またはアフィニティハンドルの使用
JPWO2011093467A1 (ja) 形質転換用プラスミド
JP2015506697A (ja) 12量体trail及びhsv−tk自殺遺伝子を同時に発現するベクター並びにそれを用いた抗癌幹細胞治療剤
Li et al. Messenger RNA-based therapeutics and vaccines: what’s beyond COVID-19?
EA011282B1 (ru) Бактериальные упаковывающие штаммы, используемые для генерирования и продуцирования рекомбинантных нуклеокапсидов с двухцепочечной рнк, и их применение
US20090011036A1 (en) Drug containing hollow protein nanoparticles of particle-forming protein, fused with disease-treating target-cell-substance
US20060105423A1 (en) Microorganisms as carriers of nucleotide sequences coding for cell antigens used for the treatment of tumors
AU2003206663B2 (en) Microorganism for genetic therapeutic treatment of proliferative diseases
JP2006502726A (ja) 改善された免疫療法
Green et al. Immune enhancement of nitroreductase‐induced cytotoxicity: Studies using a bicistronic adenovirus vector
US20220249647A1 (en) Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators
Wu et al. Functional Nucleic Acid-Based Immunomodulation for T Cell-Mediated Cancer Therapy
Barnes et al. Current strategies in gene therapy for ovarian cancer
CN113144181B (zh) 一种靶向b7h3的dna疫苗、制备方法及应用
EP1468076B1 (en) AroQ-deficient Bordetella strain and uses thereof
JP2023527910A (ja) 多用途かつ効率的な遺伝子発現のためのrnaレプリコン
WO2024113419A1 (zh) 一种具有肿瘤微环境响应的乳酸杆菌载体及应用
Sherr et al. SESSION I: TUMOUR BIOLOGY AND ANTI-TUMOUR IMMUNITY
MUKKUR Patent 2475993 Summary

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
PPPP Transfer of rights

Owner name: ZENTARIS GMBH, DE

ODRP Renewal fee for the maintenance of a patent

Payment date: 20080211

Year of fee payment: 6

OBST Application withdrawn